Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Media
A CRISPR collaboration compilation
February 19, 2024
Nature
Read Now
Press Release
A CRISPR collaboration compilation
February 19, 2024
Nature
Read Now
Media
Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
February 7, 2024
Scrip
Read Now
Press Release
Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target
February 7, 2024
Scrip
Read Now
Media
A road to survival
January 17, 2024
ASBMB Today
Read Now
Press Release
A road to survival
January 17, 2024
ASBMB Today
Read Now
Press Release
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now
Press Release
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
January 3, 2024
Read Now
Blog
